The CDER Center for Clinical Trials Innovation (C3TI) was recently created by the FDA's Center for Drug Evaluation and Research (CDER) to facilitate and expand novel approaches to clinical trials intended to increase the effectiveness of drug development. Through a consolidated knowledge repository, C3TI would disseminate information and resources on clinical trial innovation subjects through enhanced internal and external communication. Furthermore, to enable certain demonstration projects and test, implement, and scale the integration of innovation into clinical trials. Additionally, C3TI has assigned a single CDER contact to both internal and external stakeholders in order to streamline the coordination of all innovation-related inquiries. In an effort to update the guidelines for conducting clinical trials, the FDA released three guidance documents—two drafts and one final. The expanding use of decentralized clinical trials (DCTs), the increasing potential of clinical trials integrated into routine clinical practice to capitalize on the value of real-world data (RWD), and design considerations for multiregional clinical trials (MRCTs) for oncology drugs are some of the important aspects of the quickly changing clinical trial landscape that are addressed by these policies.[1]
Updates to DCT (Final guidance)
The FDA released its final DCT guidance, Conducting Clinical Trials with Decentralized Elements, in September 2024. It's interesting to note that the title was altered from the May 2023 draft advice, which was titled Decentralized Clinical Trials for Drugs, Biological Products, and Devices.
Local healthcare providers (HCPs) activities in decentralized trials have to be documented in a task log according to the original guidelines. The final guidance, however, does away with this obligation. Rather, it makes clear that local HCPs who are working within their normal area of practice need not to be well-versed on the protocol, investigator's brochure, or investigational substance. Informed permission cannot be obtained by local HCPs while the investigator are main in charge of keeping accurate records. Usually, the investigator or sub-investigator is required to supervise the administration of experimental products. However, local HCPs or remote trial staff may administer medications with well-defined safety profiles and straightforward administration. The safety profile of the product and the recommendations should be used to define the precise strategy. According to the FDA's final guidance on conducting clinical trials with decentralized elements, electronic systems must adhere to 21 C.F.R. Part 11. This implies that the FDA's requirements for electronic records and electronic signatures must be fulfilled by the electronic systems utilized in DCTs. The purpose of these standards is to guarantee the security, dependability, and correctness of electronic records. In order to reduce data variability, the final guidance emphasizes the significance of standardizing trial-related tasks carried out by regional HCPs or other trial staff. Training or video supervision, in addition to specific protocol instructions, can assist reduce this danger. Decentralized components should be explicitly described in the protocol, and study records should include information about telehealth visits, such as dates and staff names. Based on the trial population and investigational product, the appropriateness of telehealth visits should be evaluated, taking patient privacy into account. The guidelines stress that individuals without access to digital health technologies (DHTs) indicated by the protocol must be accommodated. Exclusions based on device ownership should be avoided, and other options, such as sponsor-provided telecommunications services, shoul...
(All Rights Reserved)